Nardosinone regulates the slc38a2 gene to alleviate Parkinson’s symptoms in rats through the GABAergic synaptic and cAMP pathways

Nardosinone regulates the slc38a2 gene to alleviate Parkinson’s symptoms in rats through the GABAergic synaptic and cAMP pathways
Biomed Pharmacother. 2022 Jun 18;153:113269. doi: 10.1016/j.biopha.2022.113269. Online ahead of print.ABSTRACTIn a rotenone-induced Parkinson's disease (PD) rat model, behavioral investigation, pathological examination, inflammatory factor analysis, and mitochondrial structure and function investigation verified the anti-PD efficacy of nardosinone. A combined transcriptome and proteome analysis proposed that the anti-PD target of nardosinone is the slc38a2 gene and may involve the GABAergic synaptic ... read more
Source: PubMedPublished on 2022-06-21By Li-Hua Bian